GHRH Antagonist Peptide Reduces Tumor Invasion Markers in Thyroid Cancer Without Affecting Normal Tissue | Research

The takeaway

The GHRH antagonist peptide MIA-602 reduced the activity of the invasion marker MMP-2 in papillary thyroid cancer cells while leaving normal thyroid cells unaffected.

Selective cancer-only effect
MIA-602 reduced MMP-2 invasion marker activity only in thyroid cancer cells — normal thyroid cells were completely unaffected by the treatment.

What the researchers found

Both pGHRH-R (pituitary-type GHRH receptor) and its splice variant SV1 were found to be expressed in normal thyroid and papillary thyroid cancer (PTC) cells. Treatment with the GHRH antagonist MIA-602 reduced MMP-2 activity (a marker of tumor invasion capacity) in cancer cells compared to vehicle-treated controls, while normal thyroid cells showed no change in MMP-2 activity.

Interestingly, MIA-602 increased expression of SV1 and pGHRH-R in tumor cells, which may alter signaling kinase sensitivity. However, the treatment did not affect cell proliferation rates in either tumor or normal cells, indicating anti-invasion rather than anti-proliferation activity in this setting.

Why it matters

While most papillary thyroid cancers are treatable with surgery and radioactive iodine, aggressive variants can be refractory to conventional therapy. Finding that GHRH antagonist peptides can reduce tumor invasion markers in PTC cells — without affecting normal thyroid tissue — opens a potential new therapeutic avenue for these difficult cases. The selective action on cancer cells is particularly valuable for minimizing treatment side effects.

How the study worked

In vitro study using seven normal and papillary thyroid cancer cell preparations. Cells were treated with the GHRH antagonist MIA-602 or vehicle control. Receptor expression (pGHRH-R and SV1) was assessed by Western blot. Cell proliferation was measured by standard assays. MMP-2 activity was quantified as a marker of tumor invasion potential.

What this study cannot tell us

This was an in vitro study with no animal or clinical data. The lack of anti-proliferative effect may limit standalone therapeutic utility. Only seven cell preparations were tested, and the study did not examine in vivo tumor behavior or metastasis. The mechanism behind the increased receptor expression after antagonist treatment requires further investigation. The clinical relevance of MMP-2 reduction as a surrogate for reduced invasion in actual patients is unproven.

How to read the evidence

This is an early-stage in vitro study testing a peptide antagonist on thyroid cancer cells. While the selective effect on cancer vs. normal cells is promising, no animal models or clinical data support the findings. The evidence is preliminary and mechanistic.

When this study was published

Published in 2015, this study is over a decade old. GHRH antagonist research has continued, with newer analogs being developed, but none have yet entered clinical trials for thyroid cancer specifically.

The bigger picture

GHRH antagonists represent an emerging class of peptide-based anticancer agents developed by Andrew Schally's group (a Nobel laureate for his work on hypothalamic hormones). These peptides have shown activity against prostate, brain, and other cancers by disrupting growth hormone signaling in tumors. This study extends their potential to thyroid cancer and highlights an anti-invasion mechanism rather than direct cell killing — suggesting these peptides may be most useful in preventing metastatic spread.

Questions still open

Would GHRH antagonists reduce thyroid cancer metastasis in animal models, given the MMP-2 reduction seen in vitro?
Could GHRH antagonists be combined with conventional thyroid cancer treatments to improve outcomes in aggressive PTC?
Why does the GHRH antagonist reduce invasion (MMP-2) but not proliferation in thyroid cancer cells — what signaling pathways are being differentially affected?

Common questions

What is GHRH and why would blocking it help fight cancer?

GHRH (growth hormone-releasing hormone) is a peptide that normally tells the pituitary gland to release growth hormone. Many cancers express GHRH receptors and may use this signaling pathway to support their growth and spread. By blocking these receptors with antagonist peptides, researchers aim to cut off a growth signal that cancer cells rely on.

Could this peptide become a treatment for thyroid cancer?

It's too early to say. The peptide reduced a marker of tumor invasion in lab-grown cancer cells without harming normal cells, which is encouraging. But it didn't reduce cancer cell growth, and the findings need validation in animal models and eventually human trials before it could become an actual treatment.

Read the original research

Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.

Hormones & cancer, 6(2-3), 100-6

View on PubMed ↗Publisher’s paper ↗

Citation

Catanuto, Paola; Tashiro, Jun; Rick, Ferenc G; Sanchez, Patricia; Solorzano, Carmen C; Glassberg, Marilyn K; Block, Norman L; Lew, John I; Elliot, Sharon J; Schally, Andrew V. (2015). Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.. Hormones & cancer, 6(2-3), 100-6. https://doi.org/10.1007/s12672-015-0217-2